Leading Private Equity investors understand the need to generate proprietary deals.
We leverage our deep knowledge of healthcare sector to help clients generate proprietary deals through a process of:
Our rigorous methodology and ‘two set of eyes’ quality approach has enabled private equity firms to generate proprietary deals for their platform and add-on investments in following segments:
|Client||Mid-market Private Equity firm in Western Europe|
|Situation||Client had recently acquired a CRO focusing on Phase 1-3 clinical trials for Pharma and Biotech customers. They were keen to augment the portfolio company’s capabilities by acquiring complementary assets in the US and also to broaden the services offering|
|Our approach||We leveraged our IP to generate a comprehensive database of CROs offering services that could be considered complementary to the portfolio company. Based on our research, we identified, evaluated and prioritized over 200 add-on targets and initiated contact with selected potential targets.|
|Results||Our client (mid-market private equity fund), managed to close 2 add-on deals for their CRO portfolio company, within a period of one year.|